1. Home
  2. EWTX vs AIV Comparison

EWTX vs AIV Comparison

Compare EWTX & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • AIV
  • Stock Information
  • Founded
  • EWTX 2017
  • AIV 1975
  • Country
  • EWTX United States
  • AIV United States
  • Employees
  • EWTX N/A
  • AIV N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • AIV Real Estate Investment Trusts
  • Sector
  • EWTX Health Care
  • AIV Real Estate
  • Exchange
  • EWTX Nasdaq
  • AIV Nasdaq
  • Market Cap
  • EWTX 1.5B
  • AIV 1.2B
  • IPO Year
  • EWTX 2021
  • AIV 1994
  • Fundamental
  • Price
  • EWTX $14.63
  • AIV $8.68
  • Analyst Decision
  • EWTX Buy
  • AIV
  • Analyst Count
  • EWTX 9
  • AIV 0
  • Target Price
  • EWTX $39.89
  • AIV N/A
  • AVG Volume (30 Days)
  • EWTX 723.3K
  • AIV 860.8K
  • Earning Date
  • EWTX 08-07-2025
  • AIV 08-06-2025
  • Dividend Yield
  • EWTX N/A
  • AIV 6.91%
  • EPS Growth
  • EWTX N/A
  • AIV N/A
  • EPS
  • EWTX N/A
  • AIV N/A
  • Revenue
  • EWTX N/A
  • AIV $210,828,000.00
  • Revenue This Year
  • EWTX N/A
  • AIV $6.96
  • Revenue Next Year
  • EWTX N/A
  • AIV N/A
  • P/E Ratio
  • EWTX N/A
  • AIV N/A
  • Revenue Growth
  • EWTX N/A
  • AIV 9.38
  • 52 Week Low
  • EWTX $10.60
  • AIV $6.89
  • 52 Week High
  • EWTX $38.12
  • AIV $9.49
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 58.59
  • AIV 54.33
  • Support Level
  • EWTX $13.34
  • AIV $8.60
  • Resistance Level
  • EWTX $14.08
  • AIV $8.79
  • Average True Range (ATR)
  • EWTX 0.57
  • AIV 0.16
  • MACD
  • EWTX 0.16
  • AIV -0.02
  • Stochastic Oscillator
  • EWTX 98.60
  • AIV 51.67

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.

Share on Social Networks: